STAT+: FDA and Covis release dueling documents over the fate of a controversial drug for premature births
In the run-up to an extremely unusual hearing later this month, newly released documents underscore…
Category: Pharmaceuticals
STAT+: CAR-T therapy doesn’t work in all cancer cases. Scientists are starting to figure out why
When CAR-T therapy works against blood cancer, it can work spectacularly, but cancer still returns…
STAT+: Many trials to confirm benefits of drugs granted accelerated approvals are running late
Amid heightened debate over a regulatory program for speeding the approval of some medicines, a…
STAT+: The biotech scorecard for the fourth quarter: 13 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth…
Opinion: FDA: Ignore a pharma company’s deceptive racial equity argument for keeping Makena, an ineffective preterm labor drug
In an effort to sway the Food and Drug Administration not to withdraw accelerated approval…
STAT+: Inflation caused another big drop in net drug prices, analysis finds
Amid ongoing debate over the cost of prescription medicines, a new analysis finds that brand-name…
STAT+: Pfizer accused of running a fellowship program that discriminates on racial grounds
In a move reflecting simmering controversy over diversity and equity, Pfizer has been accused of…
STAT+: Brazil dismisses antitrust complaint against Gilead over pricing for a hepatitis C drug
In a victory for Gilead Sciences, Brazilian antitrust authorities dismissed a complaint filed by several…
STAT+: Swiss authorities raid Novartis offices seeking info on patents used to block rivals
The Swiss Competition Commission has begun an investigation into Novartis over the possible unlawful use…
Tell us about your experience with telehealth linked to pharma companies
Drug ads have long tried to influence patients’ medical choices, directing them to “ask your…
STAT+: ‘This is pharma’s dream’: How drugmakers are turning telehealth into a marketing gold mine
A familiar refrain echoes through drug ads in the United States. It’s heard at the…
STAT+: J&J wins a partial appeal against the U.K.’s cost-effectiveness watchdog over ‘unfair’ review
In an unusual turn of events, an appeals panel ruled that the U.K.’s cost effectiveness…
STAT+: Even before Covid-19, remote trials saved money. Will pharma now rely on them more than ever?
Running clinical trials remotely or virtually can provide substantial financial savings for pharmaceutical companies, according…
Opinion: Listen: A doctor with ALS laments the slow pace for drug approval
During his long career as a pediatric oncologist and cancer researcher, William Woods thought highly…
.jpg)
STAT+: Bayer agrees to $40 million settlement over kickbacks and downplaying drug safety risks
After nearly two decades of litigation, Bayer agreed to pay $40 million to settle a…
STAT+: Pharmalittle: Illumina faces more challenges after winning FTC case; Novo Nordisk buys Forma Therapeutics
Good morning, everyone. I’m Jason Mast, the last of the understudies filling in while Ed…
STAT+: Pharmalittle: FDA authorizes new Covid boosters; a setback for federal efforts to regulate stem cell clinics
Good morning. This is Jonathan with you once more. We’re now close enough to the…
STAT+: Pharmalittle: An emerging star in biotech investment; U.S. government expected to stop paying for Covid shots next year
Good morning from San Diego. I’m Jonathan Wosen, STAT’s West Coast biotech reporter, and I’m…
STAT+: In a new lawsuit, pharma-backed patient groups fight federal rule around copay coupons
Three patient advocacy groups are suing the Biden administration to challenge a federal regulation they…
STAT+: Pharmalittle: FDA expected to authorize new Covid-19 boosters; Biden administration signs a deal to support monkeypox vaccine manufacturing
Good morning, everyone. I’m Allison DeAngelis, and I’m here to lead you through Tuesday’s news….
Opinion: Five years after Kymriah: Ensuring the next cell and gene therapies reach patients
Five years ago today, the Food and Drug Administration issued a landmark approval for Kymriah,…
STAT+: Centene agrees to pay $33 million to resolve another state probe into its pharmacy benefits business
Centene, one of the largest health insurers in the U.S., agreed to pay $33 million…
STAT+: Pharmalittle: House report shows Trump sought to pressure FDA on Covid response; Pfizer Covid pill provides little benefit to younger adults
Rise and shine, everyone, another busy day is on the way. Or will it be…
STAT+: Faster drug approval route sparks investment in rare kidney disease treatments
Recent years have seen a surge of research into rarer forms of kidney disease, with…
STAT+: FDA scolds Sun Pharma for allegedly backdating documents and fudging records for collecting drug samples
Sun Pharmaceutical, which is one of the largest purveyors of generic drugs, allegedly falsified various…
STAT+: Merck, a loser in the Covid vaccine race, reinvests in mRNA through a Cambridge startup
Among the most notable aspects of the Covid-19 vaccine race was who won it: Pfizer…
STAT+: Sales from controversial drug discount program rose to $44 billion last year
Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $44…
STAT+: Cancer patient who devoted six years to drug pricing reform isn’t done yet
BETHESDA, Md. — After six years of relentless advocacy work, David Mitchell was finally on…
STAT+: Novartis reports two children died from acute liver failure after treatment with Zolgensma gene therapy
Two children have died from acute liver failure after being administered Zolgensma, a pricey gene…
STAT+: With Pfizer deal, Global Blood CEO sees opportunity to reach sickle cell patients globally
The $5.4 billion acquisition of Global Blood Therapeutics by Pfizer was sealed with a phone…
STAT+: For the second time, Pfizer tries a drug warranty in response to concerns over high costs
For only the second time, Pfizer is offering a warranty for a medicine that will…
STAT+: Pharmalittle: U.S. government blunder contributed to monkeypox vax shortage; Amgen to pay $4 billion for ChemoCentryx
Top of the morning to you. Another steamy day is unfolding here at the Pharmalot…
Opinion: Are ‘modest’ drug price controls as bad for innovation as pharma claims?
Drug price controls proposed by Democrats in the U.S. Senate are being met with dire…
STAT+: Civica Rx begins selling its first generic drug as it tries to overhaul the pharmaceutical supply chain
In the latest bid to address high prescription drug costs, a nonprofit plans to sell…
STAT+: U.S. appeals court panel decides AbbVie’s ‘patent thickets’ for Humira don’t thwart competition
In a significant victory for AbbVie, a U.S. appeals court panel declined to revive a…
Opinion: Paxlovid rebound happens, though why and to whom are still a mystery
As an emergency department physician in New York, I often field calls about medical issues…
.jpg)
STAT+: A ViiV deal to license its HIV prevention shot to poor countries runs into criticism
In a much ballyhooed move, ViiV Healthcare finalized a deal to license its long-acting injectable…
STAT+: Top IQVIA lawyer declines to discuss Experian relationship, but pledges Americans’ medical secrets are safe
For years, the health data company IQVIA has quietly purchased detailed financial and demographic information…
Opinion: STAT+: How to close biopharma’s data science and engineering skills gap
In biopharma research and development, laboratory data now exist in petabytes. Today’s fastest liquid-handling robots…
STAT+: Internal documents on IQVIA’s secretive relationship with Experian undercut its image as a Fort Knox of patient data
To the outside world and its countless health care customers, the data powerhouse IQVIA has…
STAT+: AbbVie is scolded by a trade group over sales rep ‘strategically loitering’ in a hospital
In an embarrassing episode for AbbVie, the company was reprimanded by a U.K. pharmaceutical industry…
STAT+: Wyden says Merck and Abbott aren’t cooperating with probe into pharma tax practices
In his ongoing quest to probe pharmaceutical industry tax practices, the head of the U.S….
STAT+: ‘What can we do?’: Pharma lobbyists face their biggest test in a decade, as Democrats barrel toward a vote on drug pricing
WASHINGTON — The pharmaceutical industry, notorious for its deep pockets and aggressive lobbying tactics, has a…
STAT+: Despite their anger over high drug prices, Americans are giving pharma credit for helping contain Covid-19
WASHINGTON – Nearly three quarters of Americans give the pharmaceutical industry credit for helping contain…
Encouraged by right-wing doctor groups, desperate patients turn to ivermectin for long Covid
Almost two years have passed since Dean Fritzemeier fell ill with Covid in October 2020….
STAT+: McDonald’s is criticized for leaving antibiotic reduction targets off its menu
Several advocacy groups have a beef with McDonald’s over its policy for using antibiotics in…
STAT+: Biogen agrees to pay $900 million to settle whistleblower case alleging kickbacks and sham speaking events
After a decade of legal squabbling, Biogen has agreed in principle to pay $900 million…
STAT+: Pharma and advocacy groups offer competing visions for achieving vaccine equity during pandemics
Amid criticism over its approach to Covid-19, the pharmaceutical industry has issued a new “declaration”…
FDA approves first at-home therapy for skin repigmentation in vitiligo patients
Patients with vitiligo will now have access to the first ever at-home therapy for skin…
STAT+: Dozens of lawmakers urge HHS to fine drugmakers for curtailing discounts to a federal program
Dozens of lawmakers are demanding the Biden administration penalize drug companies that have curtailed discounts…